The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world, yet the total economic burden has not been quantified. Improved understanding of costs and the impact of treatment strategies will provide for better allocation of resources to reduce HCV disease and economic burden.
SUMMARY Background
The prevalence of hepatitis C virus (HCV) infection in Egypt is the highest in the world, yet the total economic burden has not been quantified. Improved understanding of costs and the impact of treatment strategies will provide for better allocation of resources to reduce HCV disease and economic burden.
Aim
A modelling approach was used to quantify the current HCV-infected population, future disease progression and associated costs in Egypt.
Methods
Direct healthcare costs were calculated from a nationally representative hospital and a disability adjusted life year (DALY) template was used with monetary value assigned to lost life years. Three scenarios were considered: (i) Historical treatment scenario: 50% SVR; 65 000 treated annually, (ii) Current treatment scenario: 90% sustained virologic response (SVR); 65 000 treated annually, (iii) Increased treatment scenario: 90% SVR; 325 000 treated annually by 2018. Results Cumulative DALYs (2015-2030) under Scenario 1 were estimated at 7.88 million and cumulative costs estimated at $89.07 billion. Annual DALYs increased 16% during 2015-2030 while annual costs more than doubled. Scenario 2 reduced cumulative DALYs and costs by 7% and 4%, respectively. Under Scenario 3, total costs declined 73% to $1047 million during [2015] [2016] [2017] [2018] [2019] [2020] [2021] [2022] [2023] [2024] [2025] [2026] [2027] [2028] [2029] [2030] . As compared to Scenario 1, cumulative DALYs and costs decreased 37% and 35%, respectively.
INTRODUCTION

The prevalence of hepatitis C virus (HCV) infection in
Egypt is the highest in the world, 1 , 2 yet the total cost and burden of chronic HCV infection on the Egyptian economy, including healthcare sector costs (direct costs), the value of lost productivity among chronically infected individuals (indirect costs), and the burden of disability associated with HCV infection have not been evaluated. Thus, the total burden on the economy remains unknown.
The total financial burden needs to be evaluated as more effective therapies with direct acting antivirals (DAAs) are introduced. 3, 4 Improved understanding of the economic cost of HCV and its major determinants helps inform policymakers to allow better allocation of resources to reduce HCV prevalence and burden. In this study, the national economic burden of hepatitis C infection in 2015 is estimated, as well as future costs, based on modelling of three scenarios, comparing to the historical case had DAAs not been adopted by the national treatment programme, to evaluate the impact of adopting highly effective therapy for HCV.
METHODS
Direct healthcare costs for each disease state were calculated using data from the National Liver Institute (NLI), a nationally representative government hospital. Direct costs were applied to HCV-infected individuals who were diagnosed and under care. To calculate indirect costs, years of life lost to disability (YLD) and years of life lost due to premature death (YLL) were estimated 5 and applied to determine cumulative disability adjusted life years (DALYs) from 2015 to 2030 and the value of lost productivity using Egyptian estimates for the value of a statistical life year (VSLY). Future disease progression was based on previously published work, 6 and costs were projected from 2015 to 2030 based on historical therapy of pegylated interferon and ribavirin (Scenario 1). The impact of changing treatment to the currently used therapies with greater efficacy (Scenario 2), as well as the additive effect of increasing the treated population and reducing new infections (Scenario 3), were considered in terms of future economic burden and compared with the historical therapeutic regimen (Scenario 1).
Population
Population data came from the Egyptian Central Agency for Public Mobilization and Statistics (CAPMAS), 7 and future estimates came from the United Nations' database. The number of patients with non-Hodgkin's lymphoma (NHL) attributed to HCV was based on published data and age-standardised incidence rates (ASR) of NHL in Egypt. [10] [11] [12] [13] The age and gender distribution of NHL was obtained from the Gharbia cancer registry. 14 The ASR of NHL in Egypt is 14.2/100 000, 13 representing approximately 12 500 new cases annually. The proportion caused by HCV infection is 42%, 13 or an estimated 4930 incident NHL cases annually. The incremental prevalence of diabetes attributable to HCV came from previously published literature. 15, 16 There were an estimated 580 240 prevalent cases of HCV-attributable diabetes in 2013 (9.7% of the viraemic population). While HCV viraemia is associated with numerous other extrahepatic manifestations (e.g. arthralgia, cryoglobulinemia, skin manifestations, sicca syndrome, thyroid disorders) and increases the risk for circulatory diseases, kidney diseases, renal failure, cancers of the oesophagus, prostate and thyroid, 17 and all cause mortality, 18 the NLI and expert opinion were used to estimate the proportion diagnosed by stage: 10% of those with chronic hepatitis, 30% of those with compensated cirrhosis and 70% of those with decompensated cirrhosis or HCC.
It was estimated that 25% of diagnosed chronic hepatitis cases were under care and incurring direct costs, compared with 50% of those with diagnosed compensated cirrhosis and 85% of those with decompensated cirrhosis and HCC. Previous analysis estimated approximately 65 000 HCV patients were treated with pegylated interferon in 2014. 6, 19 For Scenarios 1 and 2 it was assumed that 125 000 new cases were diagnosed and 65 000 patients were treated annually from 2015 to 2030, and incident cases were assumed to remain constant at 168 620 new cases annually. Scenario 2 included an increase in SVR to 90% beginning in 2015. For Scenario 3, it was assumed that the annual number diagnosed would increase sufficiently to accommodate increases in the treated population, and the number treated gradually increased up to 325 000 in 2018, based on previous analysis that showed that this is the number needed for disease control of HCV in Egypt by 2030 19 . In addition, incident cases were assumed to gradually decline to 39 930 by 2030. For all scenarios, the proportion of diagnosed patients under care was assumed to gradually reach 100% by 2030.
Direct costs
Costs were analysed for the previous year's out-patients and admitted patients at the NLI hospital. Each patient file was analysed for disease stage, medications and procedures. A more exhaustive explanation of direct costs calculations is described in Data S1. A summary of direct costs used in the analysis is shown in Table 1 .
Indirect costs
The DALY metric from the global burden of disease (GBD) study 20 was used to estimate indirect costs. It is a measure of the impact of disease on population health, combining YLLs and YLDs, weighted according to the severity of the disability. DALYs were assigned a monetary value to indicate the economic burden of disease due to loss of productivity.
To calculate YLLs and YLDs, the GBD DALY template was used as described in Data S1. 21 A separate template was used for chronic hepatitis, compensated cirrhosis, decompensated cirrhosis, HCC, NHL and diabetes.
Life expectancy by age and gender for the Egyptian population were sourced from World Health Organization (WHO) data. 22 The age-adjusted prevalence in 2015
for each stage of the disease for males and females came from the output of the model, and the age at death was estimated based on NLI admissions data. For HCC, mortality inputs came from HCC data based on 2000 cases between 2007 and 2012. 23 This study assessed the burden of disease from 2015 to 2030. When calculating YLD, the prevalent population in each year was considered with duration of disability set to 1, as the model calculated disease prevalence by stage of the disease by year. YLDs incurred before 2015 and after 2030 were not considered as part of this analysis, except for lifetime cost calculations.
The disability weights for chronic hepatitis, compensated and decompensated cirrhosis and HCC were derived from an Australian disease burden study. 24 YLLs and YLDs were calculated for individuals aged <70 years. Mortality and disability for individuals aged ≥70 years were not included in DALY and indirect cost calculations. Chronic hepatitis that is undiagnosed was assigned a weight of 0.0. Diagnosed symptomatic cases with chronic hepatitis were assigned a weight of 0.1 and compensated cirrhosis a weight of 0.3. Disability weights were set to 0.0 for cases aged <30 years for these two conditions.
For decompensated cirrhosis, the weighted average was set to 0.5 (0.4 for patients with bleeding varices being managed by repeated endoscopic management and beta blockers, 0.4 for patients with ascites on diuretic therapy, 0.8 for patients with encephalopathy or spontaneous bacterial peritonitis).
The disability weight for HCC varied according to the stage and extent of the disease. The presenting features of 770 consecutive patients in the last 3 months of 2013 were analysed: 22% stage A (weight 0.2), 32% stage B (weight 0.5), 32.5% stage C (weight 0.83), 13.5% stage D (weight 0.93) and an average disability weight of 0.6 was calculated for HCC.
The disability weight of NHL in its different stages and for diabetes was obtained from previous research. 25 It is estimated that 90% of the patients with diabetes have no major complications, and their disability weight is set to 0.07; 10% have major complications, and their disability weight is set at 0.4. Severe complications including total blindness, amputations and end stage kidney failure were rare and not considered.
Monetary value of a DALY Several methods were employed to reach an average value for a DALY: lost production represented by actual per capita annual productivity of the labour force, lost earnings based on the average national salary and VSLY (Table S1 ).
(i) Lost production: annual productivity was calculated by dividing the gross domestic product (GDP) by the labour force (ages 20-65). GDP in 2012 came from the World Bank, 26 and the labour force came from CAPMAS. 7 (ii) Lost earning: average annual salary was calculated from CAPMAS for the year 2012, and adjusted by the annual salary increase. 27 (iii) VSLY: The value of a statistical life (VSL) in Egypt was calculated from the average of the following methods:
(a) Examining the ratio between GDP per capita in Egypt to countries with published GDP and VSL values 28 A value of 1.5 for VSL elasticity was used in this study 32 where r is the discount rate (3%) and L is the life expectancy at age 9 (set to be 31 years, the life expectancy at a mean age of 46 years, 33 the mean age for patients with HCV).
(b) Per capita GDP multiple: The WHO recommended in 2001 to value a statistical life year or a DALY at one to three times per capita GDP. 30 A value of two times the per capita GDP was applied.
The mean of the output of the three methods was used to set a monetary value for a DALY. The monetary value of a DALY was $6137 by comparing the GDP/capita in Egypt to US VSL values, $6830 based on the cost of productivity of a person in the labour force in Egypt, and $6367 using the CMH2 method. Based on lost earnings (the weekly salary was $92 in 2012, 27 with estimated 20%
annual inflation to reach $110 in 2013), the average annual income was $5720 in 2013 (Table S1 ). The mean value of a DALY was $6265. The value of a DALY was assumed to increase 3% annually during 2015-2030.
Lifetime cost
To estimate lifetime costs and DALYs, a model simulation was completed where a set of 30-to 34-year-old males in a single disease stage entered the model in 2015, and disease progression and mortality were tracked for 85 years. Future lifetime costs (direct and indirect) along with DALYs were calculated by disease stage. In addition, the cost per DALY averted was calculated based on an assumed treatment cost of $2000 per cured case.
Cost-effectiveness analysis
The primary endpoint in the incremental cost-effectiveness ratio (ICER) analysis was the additional cost per DALY averted. 34 Scenario 3 is compared to Scenarios 1 and 2 ( Table 2 ). The economic feasibility of the ICER was assessed in relation to the annual per capita GDP 35 and was considered to be highly cost-effective if the ICER/DALY averted was <$3184 per DALY (1 times per capita GDP) and cost-effective if the ICER was <$9553 per DALY (three times per capita GDP).
36
RESULTS
Disease burden
Under Scenario 1, the total prevalence of HCV antibody positivity among all ages in 2008 was estimated at 12.5% as reported earlier, 37 With the use of effective DAAs under Scenario 2, there will be 8% fewer viraemic individuals and 14% fewer HCC cases in 2030 as compared to Scenario 1. The number of liver-related deaths will decrease by 15% as compared to Scenario 1 to 30 120 and decompensated cirrhosis will decrease by 20% to 104 730 prevalent cases in 2030.
Adopting Scenario 3 will result in 4 157 180 fewer viraemic individuals in 2030, a 94% reduction as compared to Scenario 1. By 2025, overall viraemic prevalence drops to 1.9%, and by 2030 viraemic prevalence is estimated at 0.3%. The number of prevalent HCC cases in 2030 is estimated to decrease by 86% to 2440 cases, and the number of liver-related deaths will decrease by 75% to 8890 deaths. Decompensated and compensated cirrhosis will decrease by 86% to 17 850 and 87 970 cases respectively. 
DALYs
Lifetime cost
Model simulation estimated the lifetime cost of a diagnosed male aged 30-34 years under care by disease state in 2015 (Figure 3) . Estimated direct lifetime costs ranged from $2150 (HCC) to $66 610 (liver transplant). Costs generally increased with disease severity; an exception is HCC, where a high mortality rate resulted in relatively low direct cost. For most disease stages, indirect costs accounted for at least 80% of total costs, ranging from $83 840 (F0) to $183 960 (decompensated cirrhosis).
Estimated lifetime DALYs ranged from 5.7 (F0) to 25.9 (HCC) (Figure 3) . Estimated YLLs ranged from 1.1 for F0 to 24.7 for HCC. Based on lifetime DALYs and assumed costs of $2000 to achieve SVR, it is estimated that the cost per DALY averted ranges from $160 (F3) up to $372 (F0). Costs per DALY averted were less than $100 for patients with decompensated cirrhosis and HCC, although these patients may be ineligible for treatment regimens.
ICERs
Adopting Scenario 3 will result in averting 2.95 million DALYs between 2015 and 2030 at a savings of $4.61 billion in direct costs and $26.89 billion in indirect costs as compared to Scenario 1, and averting 2.42 million DALYs at a savings of $5.56 billion in direct costs and $22.62 billion in indirect costs as compared to Scenario 2. For total costs, the ICER/DALY averted for Scenario 3 is À$10 670 and À$11 640, as compared to Scenarios 1 and 2 respectively (Table 2) .
DISCUSSION
Although HCV infection is a major health problem in Egypt, this is the first analysis of its total economic t r a n s p l a n t burden, including a projection of its future cost and the impact of different control strategies. Current HCV-related healthcare costs were analysed along with indirect costs due to disability and loss of life. The cost of a DALY for Egypt was calculated for the first time using the VSLY. The value used for the VSL is low (at 36-41 multiples of per capita GDP) compared with other work comparing VSL values between countries (130-195 multiples) . 38 Yet this analysis showed that HCV and its related complications form a substantial health and economic burden in Egypt. The total economic burden of HCV in Egypt is $3.81 billion, equivalent to 1.4% of GDP, relatively as large as the cost of diabetes in the US (1.45% of GDP). 39 Direct healthcare costs of HCV-related disease exceed $700 million annually and consume approximately 4.0% of the total health expenditure in Egypt, exemplifying the magnitude of the HCV epidemic in Egypt. 40 This analysis shows that while overall HCV prevalence in Egypt is declining, disease burden related to HCV and associated costs will continue to grow as the number of individuals experiencing advanced liver disease and liverrelated deaths increases. Similar trends have been modelled for other countries, 41 where peak costs lag peak prevalence by approximately three decades. US studies examining costs have found dramatic increases as patients progress to advanced liver disease, 42, 43 reiterating the importance of initiating treatment among earlier stage patients. In addition, a US study found that two-thirds of total costs associated with HCV were indirect costs. In the scenarios presented in this analysis, the cumulative direct costs during 2015-2030 as a proportion of total ranges from 26% (Scenario 1) to 33% (Scenario 3). With the current treatment strategy under Scenario 2, increased treatment efficacy alone resulted in smaller reductions in future disease burden and costs. Under Scenario 3, increases in diagnosis and treatment levels, coupled with a reduction in new cases, resulted in much larger impacts in disease and cost burden. The scenarios presented have the potential to greatly reduce the burden of HCV-related morbidity and mortality in Egypt, including a reduction in prevalence to 2.0% by 2025 under Scenario 3. Adoption of new therapies also reduces negative patient-reported outcomes associated with earlier treatment regimens, 44 but will depend upon a number of constraints. The number of diagnosed individuals needs to increase dramatically, with a similar increase in treatment. In addition, substantial reductions in prevalence are dependent upon decreased incidence. Implementation of strategies will depend upon the capacity of the healthcare system to diagnose and treat new patients, as well as executing effective measures to reduce incidence. It is anticipated that newly infected individuals may present an increased burden on the healthcare system due to long-life expectancy, highlighting the continued importance of prevention. However, if the number of diagnosed and treated patients and the average SVR are increased, prevalence can drop below 1% before 2030. As a result, it is possible that the costs averted are greater than the costs of the strategy.
A limitation of the cost analysis is uncertainty surrounding costs for extrahepatic conditions associated with chronic HCV infection, which impact up to 74% of infected individuals. 45 While incremental prevalence and costs for diabetes and NHL among HCV cases in Egypt have been well quantified, numerous other extrahepatic conditions could contribute towards the HCV-related economic burden. Remission of some extrahepatic conditions such as cryoglobulinemia is common after SVR 46 ;
however, the prevalence and associated costs for numerous other conditions after SVR have not been studied. Costs and remission rates after SVR for extrahepatic conditions could substantially impact the results of this analysis. The Egyptian National Control Strategy for Viral Hepatitis notes the importance of reducing prevalence of HCV in Egypt, as well as increasing awareness, diagnosis and treatment. 47 In addition, the national strategy highlights the importance of preventing transmission in medical settings and improving the safety of injections given in nonmedical settings. As the majority of infected individuals in Egypt are unaware of their infection, the national control strategy also emphasises efforts to increase awareness and testing for HCV. Based on our analysis, it is estimated that 70% of the prevalent population in 2015 was born between 1945 and 1975. Targeted screening efforts based on birth cohort can be efficacious for maximising diagnosis and treatment resources. 48 In conclusion, our analysis demonstrated that HCV prevalence in Egypt is declining. However, the prevalence of advanced liver disease and associated costs will continue to increase. It is possible to substantially reduce HCV disease and economic burden through increased treatment and diagnosis, along with efforts to reduce transmission. Waked has served as a speaker for Hoffman La Roche, Merck, BMS, GSK, Gilead, AbbVie; has served on advisory boards for Janssen, Hoffman La Roche, Merck and Abbott; and has acted as a principal investigator in clinical trials for Hoffman La Roche, BMS, GSK, Bayer, Janssen and AbbVie. M Abdel Kareem, W Adel Razek, E Abdelsamea, A Gomaa, W Osman, M Abuzeid and H Zaghla have no conflicts of interest to declare. Declaration of funding interests: This study was funded by Center for Disease Analysis (CDA) and National Liver Institute (NLI).
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